MedPath

Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public
Established
2006-01-01
Employees
949
Market Cap
-
Website
http://sorrentotherapeutics.com

Clinical Trials

46

Active:3
Completed:10

Trial Phases

4 Phases

Phase 1:21
Phase 2:20
Phase 3:3
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (45 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
21 (46.7%)
Phase 2
20 (44.4%)
Phase 3
3 (6.7%)
Not Applicable
1 (2.2%)

An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Phase 1
Withdrawn
Conditions
Light Chain (AL) Amyloidosis
First Posted Date
2023-01-20
Last Posted Date
2023-04-28
Lead Sponsor
Sorrento Therapeutics, Inc.
Registration Number
NCT05692908

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumor
First Posted Date
2022-10-18
Last Posted Date
2023-01-30
Lead Sponsor
Sorrento Therapeutics, Inc.
Target Recruit Count
34
Registration Number
NCT05584709
Locations
πŸ‡ΊπŸ‡Έ

Columbia University Medical Center, New York, New York, United States

Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Conditions
Long-term Follow-up
First Posted Date
2022-07-25
Last Posted Date
2023-01-23
Lead Sponsor
Sorrento Therapeutics, Inc.
Target Recruit Count
1
Registration Number
NCT05472649
Locations
πŸ‡ΊπŸ‡Έ

Abramson Cancer Center Clinical Research Unit, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents

Phase 2
Withdrawn
Conditions
COVID-19
Interventions
Drug: Placebo
First Posted Date
2022-05-13
Last Posted Date
2023-02-13
Lead Sponsor
Sorrento Therapeutics, Inc.
Registration Number
NCT05372783
Locations
πŸ‡ΊπŸ‡Έ

ProSciento, Inc., Chula Vista, California, United States

Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

Phase 1
Completed
Conditions
COVID-19
Interventions
Drug: Placebo
First Posted Date
2022-05-06
Last Posted Date
2023-01-30
Lead Sponsor
Sorrento Therapeutics, Inc.
Target Recruit Count
58
Registration Number
NCT05364840
Locations
πŸ‡¦πŸ‡Ί

Scientia Clinical Research Ltd, Randwick, New South Wales, Australia

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 10
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.